301206.SHE Shandong Sanyuan Biotechnology Co.Ltd.
- Market cap
- CNY 4.37B
- P/E
- 55.4x
- P/B
- 1.05x
- ROE
- 1.7%
- Dividend yield
- 7.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301206.SHE undervalued?
Graham number301206.SHE trades 61.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Sanyuan Biotechnology Co.Ltd. fundamental analysis
No fundamental analysis for Shandong Sanyuan Biotechnology Co.Ltd. yet.
Shandong Sanyuan Biotechnology Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Sanyuan Biotechnology Co.Ltd.
Shandong Sanyuan Biotechnology Co.,Ltd. engages in the research and development, production, and sale of erythritol and compound sugar products in China. The company products are used in table sugar, flavored sugar, and beverages; candy and chocolate food; baked food; healthy and nutritious food; pharmaceuticals and daily chemical products; chemicals and others. It exports its products to Europe, the United States, East Asia, Southeast Asia, Australia, and New Zealand. The c…
Full company profileShandong Sanyuan Biotechnology Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Sanyuan Biotechnology Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 88.9M | 121M | 292M | 477M | 783M | 1.68B | 675M | 500M | 713M | 650M | 806M |
| Gross Profit | 25.6M | 38.0M | 108M | 218M | 329M | 701M | 87.9M | 14.0M | 77.5M | 105M | 113M |
| Operating Income | 14.9M | 21.8M | 78.6M | 159M | 273M | 620M | 186M | 58.5M | 128M | 30.1M | 37.9M |
| EBITDA | 16.0M | 25.3M | 85.9M | 169M | 287M | 646M | 223M | 119M | 195M | 104M | 37.9M |
| Net Income | 13.9M | 18.7M | 68.1M | 136M | 233M | 535M | 164M | 56.0M | 105M | 91.4M | 71.5M |
| EPS | 0.16 | 0.13 | 0.47 | 0.93 | 1.53 | 3.53 | 0.82 | 0.28 | 0.52 | 0.45 | 0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 127M | 181M | 280M | 524M | 781M | 1.63B | 4.87B | 4.81B | 4.81B | 4.42B | 4.37B |
| Total Liabilities | 40.4M | 65.3M | 100M | 176M | 271M | 589M | 249M | 272M | 314M | 180M | 222M |
| Shareholders' Equity | 85.6M | 116M | 180M | 348M | 510M | 1.05B | 4.62B | 4.54B | 4.49B | 4.24B | 4.15B |
| Cash & Short-term Investments | 50.6M | 47.2M | 64.3M | 144M | 225M | 516M | 489M | 109M | 160M | 325M | 546M |
| Total Debt | - | - | 53.2M | 117M | 200M | 437M | 102M | 165M | 94.8M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 23.0M | 20.2M | 65.5M | 149M | 217M | 642M | 84.3M | 57.3M | -13.6M | 22.8M | - |
| Capital Expenditure | 12.3M | 47.3M | 48.7M | 141M | 152M | 434M | 243M | 123M | 142M | 199M | 139M |
| Free Cash Flow | 10.6M | -27.1M | 16.8M | 8.48M | 65.6M | 208M | -158M | -65.7M | -155M | -176M | 12.3M |
| Ratios | |||||||||||
| ROE | 16.3% | 16.2% | 37.9% | 39.2% | 45.6% | 51.2% | 3.5% | 1.2% | 2.3% | 2.2% | 1.7% |
| ROA | 11.0% | 10.3% | 24.3% | 26.0% | 29.8% | 32.8% | 3.4% | 1.2% | 2.2% | 2.1% | 1.6% |
| Net Profit Margin | 15.7% | 15.5% | 23.3% | 28.6% | 29.7% | 32.0% | 24.3% | 11.2% | 14.7% | 14.1% | 8.9% |
| Debt to Equity | - | - | 0.30x | 0.33x | 0.39x | 0.42x | 0.02x | 0.04x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Sanyuan Biotechnology Co.Ltd. dividends
- Dividend yield
- 7.98%
- Forward dividend
- 2.00 CNY
- Payout ratio
- 381.4%
- Ex-dividend date
- Jul 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 349M | 1.72 | 381.4% |
| 2024 | CNY 80.9M | 0.40 | 77.1% |
| 2023 | CNY 142M | 0.71 | 253.0% |
| 2022 | CNY 135M | 0.68 | 82.4% |
| 2021 | CNY 943.06 | 0.00 | 0.0% |
| 2020 | CNY 70.8M | 0.47 | 30.4% |
| 2019 | CNY 4.87M | 0.03 | 3.6% |
| 2018 | 4.87M | 0.03 | 7.1% |
| 2017 | 3.74M | 0.03 | 20.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jun 17, 2022.
Who owns Shandong Sanyuan Biotechnology Co.Ltd.
- Insiders 61.94%
- Institutions 4.74%
- Public & others 33.32%
- Shares outstanding 202M
- Free float 86.0M
Shandong Sanyuan Biotechnology Co.Ltd. company profile
- Company name
- Shandong Sanyuan Biotechnology Co.Ltd.
- Ticker
- 301206.SHE
- ISIN
- CNE100005774
- Exchange
- Shenzhen Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 441
- Fiscal year end
- December
- Address
- No. 89, Zhangfu Road, Binzhou, China, 256600
- Phone
- 86 54 3352 9851
- Website
- sanyuanbz.com
About Shandong Sanyuan Biotechnology Co.Ltd.
Shandong Sanyuan Biotechnology Co.,Ltd. engages in the research and development, production, and sale of erythritol and compound sugar products in China. The company products are used in table sugar, flavored sugar, and beverages; candy and chocolate food; baked food; healthy and nutritious food; pharmaceuticals and daily chemical products; chemicals and others. It exports its products to Europe, the United States, East Asia, Southeast Asia, Australia, and New Zealand. The company was founded in 2007 and is based in Binzhou, China.
Shandong Sanyuan Biotechnology Co.Ltd. management
5- Mr. Baohua ChengGM & Non Independent Director · born 1965
- Ms. Junling YuChief Financial Officer · born 1971
- Mr. Hongfu WeiChief Engineer & Director · born 1987
- Mr. Liang GaoBoard Secretary · born 1981
- Hui Hui LiAccounting Supervisor